Key facts
- Bluestem Biosciences’s last known valuation is $135.0M (Dec 2025).
- It has raised $21.0M across 1 recorded rounds; the latest was Early Stage VC ($5.0M) in Jul 2022.
- Notable investors include US National Science Foundation, U.S. Department of Energy, Invest Nebraska, Zero Infinity Partners, PGSA Venture Capital — 9 tracked in total.
- Bluestem Biosciences has filed 1 Form D with the SEC, most recently Aug 2022 ($5.0M sold to 19 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Bluestem Biosciences
Funding rounds
1 roundsAbout Bluestem Biosciences
Developer of a digital biology platform designed to build biology for strategic opportunities around agriculture and infrastructure. The company's platform facilitates the discovery of biomanufacturing and focuses on the sustainable production of chemicals and materials through proprietary biology built for anaerobic fermentation conditions, enabling clients to use programmable biology for the manufacturing of commodity chemicals.
- Sector
- Materials and Resources
- HQ
- Omaha, NE, United States
- Founded
- 2022
- Employees
- 11
- Website
- bluestembiosciences.com/
- Ownership
- Privately Held (backing)
Bluestem Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bluestem Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bluestem Biosciences in its N-PORT filings yet. We sweep new filings monthly.